Please login to the form below

Three key development areas in the management of multiple sclerosis



Last month, Mark Walker, our business development director, and Fabrice Allum, managing director of Porterhouse Insights, attended the ECTRIMS (European Committee for treatment and research in multiple sclerosis) congress in Berlin. This is the largest multiple sclerosis (MS) meeting in the European Scientific calendar, attracting over 10,000 delegates and covering many new developments in all areas of MS.

Mark and Fabrice identified three key themes across the meeting:

  • The use of neurofilament light chain (NfL) levels as a biomarker for disease activity and response to treatment – when neurons or axons degenerate, NfL are released into the blood or cerebrospinal fluid. Research presented at ECTRIMS shows promise for NfL as a simple biomarker of MS activity and severity that could provide a cost-effective option to support MRI. Researchers are also exploring its use in tracking brain degeneration in progressive disease and for identifying suboptimal treatment response in relapsing–remitting disease. If NfL proves to be marker of inadequate disease control, it could turn out to be revolutionary for MS management.

  • Treating early with newer (more powerful) agents – in MS, irreversible damage begins early in the disease course. It has been proposed that a change in paradigm towards effective early treatment may protect high-risk patients from further irreversible damage and loss of function. Clinical trial and real-world data supporting the efficacy of disease-modifying therapies in newly diagnosed and early MS were presented at the ECTRIMS congress. The data showed that the majority of patients remained free from confirmed disability progression, with some having been treated with disease-modifying therapies for up to nine years.

  • The importance of patient-centered care – several industry-sponsored symposia focused on the importance of improving communication between healthcare professionals and patients, and engaging/empowering patients in managing their own healthcare, to improve long-term outcomes. Two posters also highlighted the growing need for patient and public involvement (PPI) in research and clinical guideline development, which may ensure a focus on the real lives and needs of people with MS. Our teams at Porterhouse Medical Group have a strong MS heritage.
If you would like to discuss insights on MS therapy from the ECTRIMS congress in Berlin or have any questions about our experience in MS, please get in touch: https://www.porterhousemedical.com/contact/.

7th November 2018

Share

Tags

Company Details

Porterhouse Medical Group

+44 (0)118 913 9100

Contact Website

Address:
4 Windsor Square
Silver Street
Reading
RG1 2TH
United Kingdom

Latest content on this profile

Putting our mission into practice: Porterhouse Medical’s charity round-up 2018 - 2019

Porterhouse Medical Group
Creativity reaches new heights at Porterhouse Medical

Porterhouse Medical Group
Meet Porterhouse Medical at the ISMPP EU meeting 2019 in London 22 - 23 January
Porterhouse Medical’s strategic publication planning experts are participating in two events at the 2019 European Meeting of the International Society for Medical Publication Professionals, entitled: 'Scientific communications in a fast-paced world: Fighting fit for the future'.
Porterhouse Medical Group
Porterhouse Medical Group adds to its growing team of scientific and medical experts

Porterhouse Medical Group
A well-deserved promotion within Porterhouse Medical’s scientific services team

Porterhouse Medical Group
Highlights in haematologic malignancy from ASH 2018
The ASH congress is the most comprehensive haematology event of the year, over 5000 abstracts covering new developments in malignant and non-malignant haematology were presented. Here we focus on two areas of personalised medicine from the oncology setting.
Porterhouse Medical Group